-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
EIDD-1931
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/3258-02-4.gif)
| Category | Enterovirus (EV) |
| CAS | 3258-02-4 |
| Description | EIDD-1931 is a ribonucleoside analog that exhibits potential antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV. EIDD-1931 induces mutations in RNA virions, inhibiting SARS-CoV-2 and other coronavirus in mice and human airway epithelial cells. |
Product Information
| Synonyms | N4-Hydroxycytidine; N(4)-Hydroxycytidine; Uridine, 4-oxime; Beta-D-N4-hydroxycytidine |
| IUPAC Name | 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(hydroxyamino)pyrimidin-2-one |
| Molecular Weight | 259.22 |
| Molecular Formula | C9H13N3O6 |
| Canonical SMILES | C1=CN(C(=O)N=C1NO)C2C(C(C(O2)CO)O)O |
| InChI | InChI=1S/C9H13N3O6/c13-3-4-6(14)7(15)8(18-4)12-2-1-5(11-17)10-9(12)16/h1-2,4,6-8,13-15,17H,3H2,(H,10,11,16)/t4-,6-,7-,8-/m1/s1 |
| InChIKey | XCUAIINAJCDIPM-XVFCMESISA-N |
| Purity | 99.73% |
| Solubility | In Vitro: DMSO : 100 mg/mL(385.77 mM;Need ultrasonic) In Vivo: 1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (8.02 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (8.02 mM); Clear solution 3.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 2.08 mg/mL (8.02 mM); Clear solution |
| Appearance | White to off-white (Solid) |
| Storage | Powder: -20°C: 3 years 4°C: 2 years * The compound is unstable in solutions, freshly prepared is recommended. |
| Complexity | 398 |
| Exact Mass | 259.08043514 |
| In Vitro | Beta-d-N4-hydroxycytidine is an anti-VEEV (venezuelan equine encephalitis virus) agent with EC50, EC90, and EC99 are 0.426, 1.036, and 2.5 μM, respectively. Beta-d-N4-hydroxycytidine inhibits CHIKV replicon activity and the 50% effective concentration (EC50) s 0.8 μM in the Huh- 7-CHIKV replicon cell line. Similar results is presented with the replicon in BHK-21 cells (EC50=1.8 μM). NHC has no cytotoxicity for NHC in the Huh-7 cell culture system until up to 100 μM using MTT assays. The 50% cytotoxic concentration (CCsub>50) values for NHC are determined to be 30.6 μM, 7.7 μM, and 2.5 μM in peripheral blood mononuclear (PBM), Vero, and CEM cells, respectively. |
| PSA | 137.07000 |
| Target | SARS-CoV; Enterovirus; HCV; Topoisomerase |
| XLogP3-AA | -2.2 |
